Applications
XLA Screening
Newborn screening for X-linked Agammaglobulinemia (XLA) can detect the lack of KRECs within a few days after birth, facilitating an earlier diagnosis for patients with XLA and earlier initiation of treatment.
The non-invasive test from just a single blood spot sample, allows to screen for multiple conditions at once, including SCID, SMA, and XLA, ensuring that affected newborns receive early interventions that can drastically improve their quality of life.
About
the disease
X-linked Agammaglobulinemia
XLA is a genetic disorder where patients are not able to produce enough functional B-cells.
Causes
XLA is an X-linked recessive disease, when newborns suffer from a reduced immune response to infections, and the condition may be life-threatening.
XLA Prevalence
X-linked Agammaglobulinemia occurs in approximately 1 in 100,000 live births.
Because of its rarity, newborn screening plays a critical role in early detection, allowing for timely interventions that can prevent life-threatening infections in children.
Our products
portfolio
XLA Screening Products
An in vitro diagnostic (IVD) kit intended for newborn screening for severe combined immunodeficiency (SCID) and agammaglobulinemia (XLA).
Learn More
An in vitro diagnostic (IVD) kit intended for newborn screening for severe combined immunodeficiency (SCID), agammaglobulinemia (XLA), and spinal muscular atrophy (SMA) in newborns.
Learn MoreInterested in our CE marked products?